CD274 and renal cell adenocarcinoma: In recent years, ICIs—particularly those targeting PD-1 or PD-L1—have demonstrated significant survival benefits in advanced RCC, as shown in several pivotal clinical trials, including CheckMate 025, CheckMate 214, and KEYNOTE-426 (20–22).